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Abstract 
Background: Thalassemia Major is a preventable genetic disorder characterized by abnormal hemoglobin synthesis 
and lifelong blood transfusions. The children suffering from Thalassemia Major have poor quality of life. This study was 
conducted to assess the factors influencing quality of life of these children and how it can be improved.
Methods: A descriptive cross sectional study was conducted in 2014 at Thalassemia Day Care Centre of a tertiary 
level children’s hospital in Delhi, to assess quality of life of children suffering from Thalassemia Major. A total of 241 
eligible children (age 2–18 years) were enrolled in the study. Socio demographic and clinical characteristics were 
collected from interview and existing medical records. The PedsQL 4.0 generic core scale was used for assessing the 
quality of life of the children.
Results: The mean age of children was 8.69 ± 4.98 years. Two-thirds (63.5%) were boys. The total mean QoL score 
of the children was 82.0 ± 14.4. The quality of life scores were better for boys as compared to girls. The most affected 
domain was the emotional domain which showed statistically significant (p = 0.025) difference between boys and 
girls. The total QoL scores were significantly affected by the current age of the child (p = 0.000) and presence of 
co-morbidity (p = 0.026). Children not on any form of iron chelation therapy (p = 0.003) and fewer hospital visits 
(p = 0.044) had better QoL scores.
Conclusions: Factors improving the quality of life were control of iron overload and adverse effects of ICTs, manage-
ment of co morbidities and fewer hospital visits.
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Background
Thalassemia, the most common single gene disorder in 
India, is a heterogeneous group of inherited disorders 
of hemoglobin synthesis. The prevalence of carriers of 
Thalassemia gene in different regions of India varies from 
1 to 17% with a mean prevalence of about 3.3% (Modell 
and Bulyzhenkov 1988). The severe form of the disease 
(Thalassemia Major) is characterized by severe anemia 
requiring repeated blood transfusions, iron overload 
and disease related complications. The quality of life 
(QoL) and survival of children suffering from Thalas-
semia Major are considerably lower as compared to their 
normal counterparts (Thavorncharoensap et  al. 2010). 
Medical advancement with regular blood transfusion 
therapy and iron-chelating therapies (ICTs) has dramati-
cally improved the life expectancy of children suffering 
from Thalassemia Major, (Brittenham et  al. 1994; Tel-
fer et  al. 2006; Olivieri and Brittenham 1997) but their 
quality of life remains poor. There are a number of ways 
through which the quality of life may be improved, a few 
of which are simple to execute. Very few studies have 
been conducted on assessment of the modifiable predic-
tors of the same. This study is one such attempt to ana-
lyze the factors influencing the quality of life of these 
children.
Methods
A descriptive cross sectional study was conducted from 
November 2013 to March 2015 at Thalassemia Day Care 
Centre of a tertiary level children’s hospital in Delhi, for 
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assessment of quality of life of children suffering from 
Thalassemia Major. Data was collected from January 
2014 to December 2014 and the compilation, analysis 
and reporting were done from January 2015 to March 
2015. The Thalassemia Day Care center provides free 
of cost investigations, transfusion facilities, Iron chela-
tion therapy and all supportive medications along with 
food and leisure activities to the children enrolled at the 
center. A total of 453 children were enlisted of which 
241 were eligible. Children suffering from Thalassemia 
Major, regularly attending the clinic and whose parents’ 
consented for the study formed the inclusion criteria. 
Exclusion criteria were other forms of Thalassemia and 
refusal to participate in the study. All eligible children 
(age 2–18 years) diagnosed and registered for treatment 
and follow-up for Thalassemia Major were enrolled in 
the study. The children and parents were interviewed in a 
single session while the children were undergoing trans-
fusion in the centre.
Socio demographic and clinical characteristics were 
collected from interview and existing medical records. 
The PedsQL 4.0 generic core scale developed by Varni 
et  al. (1999) was used for assessing the quality of life of 
the children. This 23-item scale was used to measure the 
core dimensions of health that is physical, emotional and 
social, as well as role (school) functioning with develop-
mentally appropriate forms for ages 2–4, 5–7, 8–12 and 
13–18 years. Each item is on 5-point rating scales from 
0 to 4, labeled “Never/Almost never/Sometimes/Often/
Almost always". Psychosocial Health Summary Score 
was computed as the sum of the items over the number 
of items answered in the Emotional, Social, and School 
Functioning Scales together. The  Physical Health Sum-
mary Score  was the same as the Physical Functioning 
Scale Score. For the Total Scale Score, the mean was cal-
culated by sum of all the items over the number of items 
answered on all the Scales. Thorough physical exami-
nation of the children was done following the admin-
istration of questionnaire and the investigations were 
obtained from the hospital records.
Permission was taken from MAPI Research Institute, 
Lyon, France prior to using the instrument and Hindi 
translation of the same was obtained. Written informed 
consent of the parents/guardians and assent of the chil-
dren was obtained. The study protocol was approved by 
Institutional ethical committee of Lady Hardinge Medi-
cal College, New Delhi, India.
Data analysis was done using Microsoft excel and Sta-
tistical Package for the Social Sciences (SPSS) version 
11.5. Data was expressed as mean (SD), median (range) 
and proportions. The categorical variables were analyzed 
using Chi square and Fischer’s exact test. The differ-
ences between groups were analyzed by unpaired t-test 
and Mann–Whitney U test. Pearson’s or Spearman’s rank 
correlation coefficients were used to find out strength of 
relationships. Multiple regression analysis was done in a 
stepwise manner to identify independent predictors. All 
p values were two tailed at a significance level of 0.05.
Results
All 241 children responded to the questionnaire, giving 
a response rate of 100%. The mean age of children was 
8.69 ± 4.98 years (range: 2–18 years). Two-thirds (63.5%) 
were boys and almost all (97.9%) were from urban back-
ground with majority (71.4%) belonging to Hindu reli-
gion. Nearly half (53%) of the subjects belonged to 
middle socioeconomic status and almost same propor-
tion (53.5%) belonged to nuclear families. Consanguine-
ous marriage was reported by parents of 19.6% of study 
subjects. About 1/3rd (28.6%) of the subjects reported 
history of Thalassemia major in the family (Table 1).
A total of 173 children were of school going age of 
which 89.5% were currently attending school and 8.6% 
were school dropouts. A few children (1.7%) were never 
enrolled in school. The main reasons for dropout were 
health problems (66.7%) followed by financial constraints 
(13.3%). Delayed schooling was observed in 42.4% of all 
the study subjects. Almost 1/3rd (28.3%) of the mothers 
and 18.3% of the fathers of study subjects were illiterate. 
Majority (88%) of the mothers were homemakers. Half 
(49.7%) of the fathers were employed as unskilled and 
semi-skilled workers while only 5.9% had a professional 
background.
The mean age at onset of Thalassemia was 
8.2 ± 7.1 months (range: 0.5–36 months). The mean age 
at diagnosis was 9.2 ± 7.4 months (range: 1–36 months). 
Almost half of the study subjects (45.2%) had hemolytic 
facies. Delayed puberty was observed in 7.8% of the 
boys and 5.7% of the girls. Seventeen (7.1%) of the study 
subjects were suffering from co-morbidities. Majority 
(88.4%) of the subjects were on only oral iron chelation 
therapy. Twenty-one (8.7%) of the study subjects were 
not on any form of iron chelation therapy because of con-
trolled ferritin levels. Side effects were observed in 11.8% 
of the study subjects on ICT.
The mean health related quality of life (HRQoL) scores 
are shown in Table  2 which summarizes physical, emo-
tional, social school functioning, psychosocial health and 
total summary score. The total mean QoL score of the 
children enrolled at the center was 82.0 ± 14.4. The total 
quality of life scores were better for boys as compared to 
girls but this difference was not statistically significant 
(p = 0.131). The most affected domain was the emotional 
domain which was better for boys (77.7 ± 15.9) as com-
pared to girls (71.5 ± 19.1) and this difference was statis-
tically significant (p = 0.025).
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The total QoL scores were significantly affected by the 
current age of the child (p < 0.001). Presence of co-mor-
bidity significantly altered the quality of life scores across 
all domains (p = 0.026). Children not on any form of iron 
chelation therapy had better QoL scores as compared to 
those on any form (p =  0.003). Fewer visits to the hos-
pital were associated with better quality of life scores 
(p = 0.044) (Table 3).
A strong negative correlation of the physical domain 
scores was observed with current age of the child. 
Younger patients had higher total summary scores as 
compared to older patients (p  <  0.001). Based on clini-
cal characteristics, age at onset (p  =  0.017), frequency 
of transfusions per month (p =  0.009), treatment dura-
tion (p  <  0.001), number of concomitant medicines 
(p = 0.011) and co morbidities (p = 0.007) were signifi-
cantly associated with self reported Physical summary 
scores (Table 3).
A multiple linear regression was run to predict physical 
quality of life scores from current age of the child, age at 
onset, number of concomitant medications and co-mor-
bidities, frequency of transfusions per month and dura-
tion of treatment. These variables together statistically 
significantly predicted physical quality of life (R = 0.325, 
R2 = 0.106, p = 0.000). 10.6% of all variation in the physi-
cal quality of life scores was due to these independent 
variables (Table 4).
Psychosocial domain scores strongly correlated with 
age in completed years (p = 0.000), duration of treatment 
(p  =  0.001) and number of visits per year (p  =  0.011). 
Multiple linear regression predicted that about 4.4% of 
the variation in the psychosocial quality of life score was 
due to these three variables. The variables statistically sig-
nificantly predicated the scores. (R = 0.211, R2 = 0.044, 
p < 0.001) as shown in Table 4.
The mean scores of total quality of life scores were neg-
atively predicted by current age of the child (p < 0.001), 
age at onset (p  =  0.025), frequency of transfusions 
(p = 0.050), duration of treatment (p < 0.001), total num-
ber of visits per year (p = 0.006), number of concomitant 
medicines (p  =  0.013) and number of co-morbidities 
(p = 0.024). The Multiple linear regression run between 
these variables and total quality of life scores showed 
that these variables statistically significantly predicted 
the total quality of life scores, (R  =  0.310, R2  =  0.096, 
p = 0.001). 9.6% of the variation in the total quality of life 
scores was due to these variables (Table 4).
Discussion
The QoL in the present study was measured using Ped-
sQL 4.0 generic core scales. A normal child should 
have a score of or closer to 100 for all domains in this 
Table 1 Socio-demographic and  clinical characteristics 
of 241 children suffering from Thalassemia
a Others included Sikh and Christian
Socio-demographic and clinical characteristics n = 241
Mean age (years) 8.69 ± 4.98
Sex
 Male 153 (63.5%)
 Female 88 (36.5%)
Religion
 Hindu 172 (71.4%)
 Muslim 60 (24.9%)
 Othersa 9 (3.7%)
Socioeconomic status
 Upper 0 (0%)
 Middle 122 (53%)
 Lower 103 (44.8%)
 Not applicable (rural) 5 (2.2%)
Type of family
 Joint 107 (46.5%)
 Nuclear 123 (53.5%)
Consanguinity
 Yes 47 (19.6%)
 No 194 (80.4%)
Family history of Thalassemia
 Yes 69 (28.6%)
 No 172 (71.4%)
Age at onset (months)
 0–6 165 (68.5%)
 7–12 40 (16.6%)
 13–18 14 (5.8%)
 19–24 14 (5.8%)
 >24 8 (3.3%)
Presence of co-morbidities/complications
 Yes 17 (7.1%)
 No 224 (92.9%)
Iron chelation therapy
 Yes 220 (91/3%)
 No 21 (8.7%)
Table 2 Health-related quality of  life (HRQoL) of  the chil-
dren with Beta-Thalassemia major
Values are expressed as mean (standard deviation; SD), Statistical methods used: 








Physical QoL score 81.3 ± 21.3 82.3 ± 18.7 79.5 ± 25.1 0.121
Psychosocial QoL 
score
82.5 ± 13.1 83.7 ± 11.8 80.5 ± 14.8 0.079
Emotional domain 75.4 ± 17.4 77.7 ± 15.9 71.5 ± 19.1 0.025
Social domain 92.0 ± 17.4 92.8 ± 15.9 90.6 ± 19.7 0.335
School functioning 77.8 ± 14.5 77.5 ± 15.6 78.2 ± 12.7 0.930
Total QoL score 82.0 ± 14.4 83.1 ± 12.5 80.1 ± 17.2 0.131
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questionnaire. The quality of life scores of the 241 chil-
dren in the present study were low as compared to the 
normal children (total summary score: 82.0 ± 14.4, psy-
chosocial summary score: 82.5 ± 13.1 and physical health 
score: 81.3 ± 21.3).
Scores across all domains were higher in present study 
as compared to other studies (Ayoub et al. 2013; Caocci 
et  al. 2012; Gharaibeh and Gharaibeh 2012; Wahyuni 
et  al. 2011; Surapolchai et  al. 2010; Clarke et  al. 2010; 
Ismail et  al. 2006). This may be attributed to the better 
access to health care facilities and better control of iron 
overload related complications at this tertiary care center. 
The parents and children are informed about the next 
transfusion beforehand which is calculated as per their 
rate of fall in hemoglobin level. The children are thor-
oughly assessed for iron overload and co-morbidities at 
every visit by a resident doctor and any investigation and 
intervention required is done as soon as possible, free of 
cost.
The total summary scores were higher among boys in 
our study as compared to girls though the difference was 
not statistically significant. The lower scores in girls may 
be due to poor attention given to girl child in our society. 
On the contrary, some studies (Caocci et  al. 2012; Saha 
et al. 2015) have reported better scores for girls and other 
studies have shown no difference between boys and girls 
(Thavorncharoensap et  al. 2010; Gharaibeh and Gharai-
beh 2012; Torcharus and Pankaew 2011).
Age was an important predictor for all the three sum-
mary scores of the quality of life questionnaire. One 
explanation for the higher scores in younger ages is the 
recent onset of disease resulting in less iron overload 
and hence lesser complications. A rise in the quality of 
life scores in all domains was observed in the age group 
of 13–18 years after a dip in the age group of 8–12 years. 
The observation is probably due to the process of adapta-
tion of the teenage group to the lifestyle associated with 
Thalassemia.
Children who had any form of co morbidity had poorer 
total quality of life scores as compared to those who did 
not (p < 0.001). Absence of co morbidities improves the 
overall quality of life. Co-morbidities affect both the 
physical and psychological quality of life severely. The 
number of co morbidities was a strong predictor of the 
poor physical and total quality of life score (Table 4).
Introduction of iron chelation therapy (ICT) has been 
a boon in the management of Thalassemia but it has its 
own pros and cons. Only 8.7% of the children in the pre-
sent study were not on any form of iron chelation therapy 
(ICT). The rest were on either oral or subcutaneous or 
both forms of ICT. The total quality of life scores were 
better for children who were not on any form of ICT 
(p = 0.003), since the children were not exposed to ICT 
associated side effects like nausea, pain in joints, and pain 
at the site of injection (in case of subcutaneous therapy) 
which hamper the normal day to day activities of the 
Table 3 Univariate analysis on covariates associated with HRQoL scores among children with Beta-Thalassemia Major
Values are expressed as mean (standard deviation; SD), Statistical methods used: Mann–Whitney U test for difference between groups, Correlation coefficient 
measured for correlation; * p < 0.05 was considered statistically significant
Physical  
QoL Score








p value Correlation 
(r, p)
Age
 2–4 years (n = 68) 88.9 ± 21.6 0.001 (−0.243, 0.000) 86.1 ± 12.6 0.000 (−0.229, 
0.000)
87.4 ± 14.2 0.000 (−0286, 0.000)
 5–7 years (n = 43) 83.2 ± 16.4 85.5 ± 10.7 84.5 ± 10.7
 8–12 years (n = 61) 75.7 ± 23.5 77.7 ± 14.3 76.7 ± 15.6
 13–18 years (n = 69) 77.5 ± 19.4 81.5 ± 12.4 79.9 ± 13.6
Comorbidity
 Yes (n = 17) 67.0 ± 25.9 0.008 (−0.173, 0.007) 76.9 ± 16.6 0.157 (−0.093, 
0.150)
72.8 ± 18.5 0.026 (−0.145, 0.024)
 No (n = 234) 82.4 ± 20.5 82.9 ± 12.7 82.7 ± 13.9
Type of Iron chelation therapy
Only oral (n = 213) 81.2 ± 21.3 0.103 82.0 ± 12.4 0.000 81.7 ± 13.9 0.003
Only subcutaneous 
(n = 3)
67.7 ± 17.8 78.3 ± 19.2 74.6 ± 17.2
Oral +subcutaneous 
(n = 4)
73.4 ± 14.6 75.4 ± 12.5 74.6 ± 13.0
No ICT (n = 21) 86.1 ± 21.9 89.7 ± 17.2 88.1 ± 18.6
Frequency of Hospital visits/month
1 (n = 196) 83.1 ± 20.4 0.012 (−0.162, 0.009) 82.9 ± 12.9 0.213 (−0.50,0.420) 82.9 ± 14.1 0.044 (−0.127, 0.050)
2 (n = 43) 74.6 ± 23.2 81.3 ± 13.5 78.7 ± 15.4
3 (n = 2) 51.6 ± 6.6 69.2 ± 1.2 63.0 ± 3.07
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children. Children on oral iron chelation therapy had 
higher scores compared to those on combined oral and 
subcutaneous therapy. The painful subcutaneous injec-
tions greatly affect the psychosocial health. Torcharus 
et al. (2011) reported no difference in QOL based on type 
of iron chelation therapy while Surapolchai et al. (2010) 
and Thavorncharoensap et al. (2010) reported significant 
difference in quality of life scores due to iron chelation 
therapy.
Frequency of blood transfusion and the total number of 
visits per year were predictors of physical and total qual-
ity of life scores and negatively affected QoL scores in the 
present study. Children with 1 transfusion per month had 
better total QoL scores as compared to children visiting 3 
times a month for transfusion. More frequent visits to the 
hospital have negative impact on children’s lives in terms of 
physical burden, psychological burden and school attend-
ance thus affecting the quality of life. Children have a con-
stant stress of travelling all the way from long distances and 
being subjected to painful investigations and transfusion 
procedures. This finding was comparable to that reported 
by Surapolchai et  al. (2010) while Caocci et  al. (2012) 
reported no relation between visits and HRQoL scores.
The independent variables for predicting the total qual-
ity of life score viz current age, age at onset, frequency 
of transfusions, duration of treatment, total number of 
visits per year, number of concomitant medicines and 
number of co-morbidities predicted only 9.6% of the 
variation in the total quality of life scores. Some of these 
factors like age of the child, age of onset are non-modifia-
ble, while rest can be improved by regular treatment and 
better clinical management as indicated by the study. On 
the contrary Saha et al. (2015) showed variation in total 
QoL score due to variables like duration since splenec-
tomy, last pre transfusion Hb level and family history of 
thalassemia, which were not significant predictors in the 
present study.
Apart from clinical management of the disease, another 
major factor affecting the overall quality of life of the 
children is the availability of health care services free of 
cost. Every service right from the blood transfusion kit to 
the cost of travel drains a lot of money from the family 
savings. A big contribution of the center is the provision 
of free blood, drugs, food, passes for travel and investiga-
tions which has been a major contributory factor for the 
overall improvement of quality of life.
Conclusion
Thalassemia is a disease which impairs the quality of life 
of children significantly. Major factors affecting the qual-
ity of life are related to better control of iron overload 
and adverse effects of ICTs, prevention of co morbidities, 
fewer hospital visits and good clinical management. Early 
diagnosis, regular monitoring, education and financial 
support are the major areas of intervention to improve 
the overall quality of life of these children.
Table 4 Multiple linear regression analysis on predictors of the HRQoL scores on subscales of Peds QoL reports
Statistical method used: multiple linear regression; * p < 0.05 was considered statistically significant
R R2 F (DF, P) β coefficient p value*
Physical QoL 0.325 0.106 4.617 (6, 234) 105.468 0.000
 Age in completed years 0.459 0.647
 Age of onset in months −1.913 0.057
 Number of comorbidities −1.665 0.097
 Duration of treatment in years −0.687 0.493
 Frequency of transfusion per month −1.959 0.051
 Number of Concomitant medications −1.510 0.132
Psychosocial QoL 0.211 0.044 3.663 (3, 237) 88.327 0.013
 Age in completed years −2.309 0.207
 Duration of treatment 1.432 0.441
 Total number of visits per year −0.101 0.793
Total QoL 0.310 0.096 3.536 (7, 233) 97.264 0.001
 Age in completed years −0.012 0.994
 Age of onset in months −0.280 0.109
 Frequency of transfusion per month −2.529 0.305
 Duration of treatment in years −0.408 0.806
 Number of Concomitant medications −2.193 0.213
 Total number of visits per year −0.093 0.741
 Number of comorbidities −4.902 0.094
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